NEUROprotection Via optimizINg Cerebral Blood Flow afTer cArdiaC arresT (NEURO-INTACT) Study
Condition(s) studied
Investigational drug(s) / intervention(s)
Individualized blood pressure strategy: An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.
Study summary
This single-center proof of concept study aims to assess the efficacy of a blood pressure strategy targeting person- and time-specific cerebral blood flow compared with standard-of-care using neuron-specific enolase as a quantitative biomarker of brain injury. Our central hypothesis is that an individualized blood pressure strategy targeting cerebral perfusion will reduce the extent of brain injury as indicated by changes in levels of neuron-specific enolase from baseline at 72 hours. To test this hypothesis, we will recruit 49 patients to an individualized blood pressure management strategy targeting cerebral blood flow, where optimal blood pressure will be serially calculated by the ICM+ brain monitoring software (Cambridge, UK) using inputs from transcranial Doppler ultrasound and near-infrared spectroscopy.
Eligibility
Primary outcome measure(s)
- Mean change in neuron-specific enolase (NSE) — 72 hours post ROSC
The mean change in concentration of NSE from baseline levels to 72 hours post-ROSC.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| National University Heart Centre, Singapore | Singapore | Singapore | Recruiting |
More National University Hospital, Singapore trials in Singapore
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05679739 on ClinicalTrials.gov ↗ ← All trials in Singapore